Sarcomas | Specialty

Dr. Pollack on the Role of Radiomics in Sarcoma

December 13th 2016

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma.

Dr. Dimosthenis on Prognosis Factors in Ewing Sarcoma

December 2nd 2016

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.

Pembrolizumab Antitumor Activity Promises Potential for Sarcoma Subtypes

November 15th 2016

Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.

Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma

November 12th 2016

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

EC Approves Frontline Olaratumab for Soft Tissue Sarcoma

November 12th 2016

The European Commission has granted an accelerated approval to olaratumab in combination with doxorubicin as a frontline therapy for patients with advanced soft tissue sarcoma, making it the first new therapy for this indication in over 40 years.

Dr. Albertsmeier on the Effect of Radiation on Local Recurrence and OS in Soft Tissue Sarcoma

November 10th 2016

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses a a meta-analysis of the effect of radiation therapy on local recurrence and overall survival in patients with soft tissue sarcoma.

Final Thoughts on STS

November 8th 2016

Toxicity of Olaratumab and Doxorubicin

November 8th 2016

Sequencing with Olaratumab in STS

November 8th 2016

Appropriate Patients for Olaratumab + Doxorubicin

November 8th 2016

OS vs PFS with Olaratumab

November 8th 2016

Practical Implications of Using Olaratumab in Patients with STS

November 8th 2016

Registration Trials for Olaratumab and Doxorubicin for STS

November 8th 2016

FDA Approval of Olaratumab + Doxorubicin for STS

November 8th 2016

Multidisciplinary Care of STS

November 8th 2016

Disease State: Advanced Soft Tissue Sarcoma

November 8th 2016

Eribulin Shows Efficacy in Leiomyosarcoma, Further Research Needed

November 3rd 2016

A subgroup analysis from a phase III, open-label, randomized study showed that eribulin had comparable activity to dacarbazine in patients with leiomyosarcoma.

Dr. Elizabeth H. Baldini on Systemic Therapy for Sarcoma

November 2nd 2016

Elizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma

FDA Approves Olaratumab for Soft Tissue Sarcoma

October 19th 2016

The FDA has granted an accelerated approval olaratumab in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.

Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

October 18th 2016

​Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.